Abstract
Multiple myeloma (MM) is a B-cell neoplasia caused by the proliferation of clonal plasma cells, primarily in the bone marrow (BM). The role of the BM microenvironment in the pathogenesis of the disease has been demonstrated, especially for the survival and growth of the myeloma plasma cells. Functional characterization of the major component of the BM microenvironment, namely the recently characterized mesenchymal stem cells (MSCs), was never performed in MM. Based on a series of 61 consecutive patients, we evaluated the ability of MSCs derived from myeloma patients to differentiate into adipocytes and osteocytes, inhibit T-cell functions, and support normal hematopoiesis. MSCs phenotypic characterization and quantification of interleukin-6 (IL-6) secretion were also performed. As compared to normal MSCs, MSCs from MM patients exhibited normal phenotype, differentiation capacity and long-term hematopoietic support, but showed reduced efficiency to inhibit T-cell proliferation and produced abnormally high amounts of IL-6. Importantly, these characteristics were observed in the absence of any detectable tumor plasma cell. Chromosomal analysis revealed that MM patients MSCs were devoid of chromosomal clonal markers identified in plasma cells. MM MSCs present abnormal features that may participate in the pathogenesis of MM.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC . Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104: 607–618.
Lauta VM . A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 2003; 97: 2440–2452.
Hallek M, Bergsagel PL, Anderson KC . Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3–21.
Dalton WS . The tumor microenvironment: focus on myeloma. Cancer Treat Rev 2003; 29 (Suppl 1): 11–19.
Gunn WG, Conley A, Deininger L, Olson SD, Prockop DJ, Gregory CA . A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and Interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006; 24: 986–991.
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD et al. Multilineage potential of adult mesenchymal stem cells. Science 1999; 284: 143–147.
Prockop DJ . Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71–74.
Silva Jr WA, Covas DT, Panepucci RA, Proto-Siqueira R, Siufi JL, Zanette DL et al. The profile of gene expression of human marrow mesenchymal stem cells. Stem Cells 2003; 21: 661–669.
Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838–3843.
Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D . Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4619–4621.
Rasmusson I, Ringden O, Sundberg B, Le Blanc K . Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005; 305: 33–41.
Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367–372.
Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120–4126.
Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M . Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74–85.
Tricot G . New insights into role of microenvironment in multiple myeloma. Lancet 2000; 355: 248–250.
Epstein J, Yaccoby S . Consequences of interactions between the bone marrow stroma and myeloma. Hematol J 2003; 4: 310–314.
Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL . The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998; 92: 3025–3034.
Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O . Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57: 11–20.
Yeh SP, Chang JG, Lo WJ, Liaw YC, Lin CL, Lee CC et al. Induction of CD45 expression on bone marrow-derived mesenchymal stem cells. Leukemia 2006; 20: 894–896.
Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC . Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993; 82: 3712–3720.
Klein B, Zhang XG, Lu ZY, Bataille R . Interleukin-6 in human multiple myeloma. Blood 1995; 85: 917–924.
Caligaris-Cappio F, Bergui L, Gregoretti MG, Gaidano G, Gaboli M, Schena M et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991; 77: 2688–2693.
Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM . Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer 2001; 91: 1219–1230.
Potter M . Neoplastic development in plasma cells. Immunol Rev 2003; 194: 177–195.
Arnulf B, Bengoufa D, Sarfati E, Toubert ME, Meignin V, Brouet JC et al. Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism: a prospective study. Arch Intern Med 2002; 162: 464–467.
Streubel B, Chott A, Huber D, Exner M, Jager U, Wagner O et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004; 351: 250–259.
Rigolin GM, Fraulini C, Ciccone M, Mauro E, Bugli AM, De Angeli C et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 2006; 107: 2531–2535.
Hendrix MJ, Seftor EA, Hess AR, Seftor RE . Vasculogenic mimicry and tumor-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003; 3: 411–421.
Aggarwal S, Pittenger MF . Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815–1822.
Acknowledgements
Séverine Lecourt was supported by research grant from Genostem.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Arnulf, B., Lecourt, S., Soulier, J. et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 21, 158–163 (2007). https://doi.org/10.1038/sj.leu.2404466
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404466
Keywords
This article is cited by
-
Lipid metabolic vulnerabilities of multiple myeloma
Clinical and Experimental Medicine (2023)
-
Phenotypic and functional alterations of bone marrow MSCs exposed to multiple myeloma cells
Molecular & Cellular Toxicology (2023)
-
Mesenchymal stromal cell senescence in haematological malignancies
Cancer and Metastasis Reviews (2023)
-
Interleukin-8 release by endothelial colony-forming cells isolated from idiopathic pulmonary fibrosis patients might contribute to their pathogenicity
Angiogenesis (2019)
-
Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism
Scientific Reports (2019)